GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Walvax Biotechnology Co Ltd (SZSE:300142) » Definitions » EBIT

Walvax Biotechnology Co (SZSE:300142) EBIT : ¥454 Mil (TTM As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Walvax Biotechnology Co EBIT?

Walvax Biotechnology Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥61 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥454 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Walvax Biotechnology Co's annualized ROC % for the quarter that ended in Mar. 2024 was 4.28%. Walvax Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 4.53%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Walvax Biotechnology Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 2.45%.


Walvax Biotechnology Co EBIT Historical Data

The historical data trend for Walvax Biotechnology Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Walvax Biotechnology Co EBIT Chart

Walvax Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 260.02 1,373.90 714.72 1,077.57 604.93

Walvax Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 212.01 418.74 147.23 -173.05 60.64

Competitive Comparison of Walvax Biotechnology Co's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Walvax Biotechnology Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Walvax Biotechnology Co's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Walvax Biotechnology Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Walvax Biotechnology Co's EV-to-EBIT falls into.



Walvax Biotechnology Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥454 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Walvax Biotechnology Co  (SZSE:300142) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Walvax Biotechnology Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=588.3 * ( 1 - 33.08% )/( (9168.075 + 9242.696)/ 2 )
=393.69036/9205.3855
=4.28 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=15588.869 - 2056.259 - ( 4364.535 - max(0, 3203.907 - 8733.17+4364.535))
=9168.075

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=15386.882 - 2031.698 - ( 4112.488 - max(0, 2977.683 - 8496.107+4112.488))
=9242.696

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Walvax Biotechnology Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=242.54/( ( (3768.35 + max(1352.432, 0)) + (3986.717 + max(1598.884, 0)) )/ 2 )
=242.54/( ( 5120.782 + 5585.601 )/ 2 )
=242.54/5353.1915
=4.53 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3100.608 + 1034.637 + 70.161) - (2056.259 + 0 + 796.715)
=1352.432

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3059.378 + 1100.93 + 59.832999999999) - (2031.698 + 0 + 589.559)
=1598.884

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Walvax Biotechnology Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=453.549/18524.933
=2.45 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Walvax Biotechnology Co EBIT Related Terms

Thank you for viewing the detailed overview of Walvax Biotechnology Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Walvax Biotechnology Co (SZSE:300142) Business Description

Traded in Other Exchanges
N/A
Address
Keyuan Road No. 99, 19th Floor, Building 9A, Dingyi Tiancheng Residential Quarter, High & New Tech Development Zone, Yunnan Province, Kunming, CHN, 650106
Walvax Biotechnology Co Ltd biological pharmaceutical enterprise engaged in research and development, production and sales of bio-medicine products. It offers bio-medicines, such as vaccines, blood products, and others. The company's products include Haemophilus influenza type b conjugate vaccines, freeze-dried group A, C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines, and group A and C meningococcal polysaccharide vaccines.
Executives
Wu Yun Yan Executives
Zhao Jin Long Executives
Yao Wei Executives
Zhou Hua Executives
Shi Jing Executives
Jiang Run Sheng Directors, executives
Gong Sun Qing Executives
Executives
Yuan Lin Executives
Fang Guo Liang Executives
Li Yun Chun Director
Huang Zhen Director
Zhang Li Secretary Dong
Yang Hong Wei Supervisors
Xu Ke Ren Executives

Walvax Biotechnology Co (SZSE:300142) Headlines

No Headlines